Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AC176 |
Synonyms | |
Therapy Description |
AC176 is an androgen receptor (AR) degrader, which induces proteosomal degradation of AR, resulting in decreased target gene expression and potentially leading to reduced tumor cell growth (PMID: 38030789). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AC176 | AC-176|AC 176|AC0176 | Hormone - Anti-androgens 54 | AC176 is an androgen receptor (AR) degrader, which induces proteosomal degradation of AR, resulting in decreased target gene expression and potentially leading to reduced tumor cell growth (PMID: 38030789). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05241613 | Phase I | AC176 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |